Risultati della ricerca - Ingrid Gause‐Nilsson

Raffina i risultati
  1. 1
    Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis

    Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis di Christian Sonesson, Peter A. Johansson, Eva Johnsson, Ingrid Gause‐Nilsson

    Pubblicazione 2016
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  2. 2
    Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial

    Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial di Burkhard Göke, B. Gallwitz, Johan G. Eriksson, Å. Hellqvist, Ingrid Gause‐Nilsson

    Pubblicazione 2010
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  3. 3
    Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial

    Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomi... di Burkhard Göke, Baptist Gallwitz, Johan G. Eriksson, Åsa Hellqvist, Ingrid Gause‐Nilsson

    Pubblicazione 2013
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  4. 4
    Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

    Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus di André Scheen, G. Charpentier, Carl Johan Östgren, Åsa Hellqvist, Ingrid Gause‐Nilsson

    Pubblicazione 2010
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  5. 5
    Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin‐angiotensin blockers

    Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin‐angiotensin blockers di Hiddo J.L. Heerspink, Eva Johnsson, Ingrid Gause‐Nilsson, Valerie A. Cain, C. David Sjöström

    Pubblicazione 2016
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  6. 6
    Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study

    Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy a... di Michał Nowicki, Ivan Rychlík, Hermann Haller, Mark Warren, Lisa Suchower, Ingrid Gause‐Nilsson, K-M. Schützer

    Pubblicazione 2011
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  7. 7
    Dapagliflozin’s Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension

    Dapagliflozin’s Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled... di William T. Cefalu, Lawrence A. Leiter, Tjerk W.A. de Bruin, Ingrid Gause‐Nilsson, Jennifer Sugg, Shamik Parikh

    Pubblicazione 2015
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  8. 8
    Tesaglitazar, a novel dual peroxisome proliferator-activated receptor α/γ agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population

    Tesaglitazar, a novel dual peroxisome proliferator-activated receptor α/γ agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non... di Björn Fagerberg, S. Edwards, T Halmos, J Łopatyński, H. Schuster, Steen Stender, Grethe Støa-Birketvedt, Serena Tonstad, Sigrún Halldórsdóttir, Ingrid Gause‐Nilsson

    Pubblicazione 2005
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  9. 9
    Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58

    Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58 di Avivit Cahn, Stephen D. Wiviott, Ofri Mosenzon, Erica L. Goodrich, Sabina A. Murphy, Ilan Yanuv, Aliza Rozenberg, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John Wilding, Ingrid Gause‐Nilsson, Anna Maria Langkilde, Marc S. Sabatine, Itamar Raz

    Pubblicazione 2022
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  10. 10
    <scp>DECLARE‐TIMI</scp> 58: Participants’ baseline characteristics

    <scp>DECLARE‐TIMI</scp> 58: Participants’ baseline characteristics di Itamar Raz, Ofri Mosenzon, Marc P. Bonaca, Avivit Cahn, Eri Kato, Michael G. Silverman, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John Wilding, Ingrid Gause‐Nilsson, Anna Maria Langkilde, Peter A. Johansson, Marc S. Sabatine, Stephen D. Wiviott

    Pubblicazione 2018
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  11. 11
    Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE–TIMI 58 trial

    Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE–TIMI 58 trial di Kazuma Oyama, Itamar Raz, Avivit Cahn, Julia Kuder, Sabina A. Murphy, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John Wilding, Kyong Soo Park, Assen Goudev, Rafael Díaz, Jindřich Špinar, Ingrid Gause‐Nilsson, Ofri Mosenzon, Marc S. Sabatine, Stephen D. Wiviott

    Pubblicazione 2021
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  12. 12
    Cardiorenal outcomes with dapagliflozin by baseline glucose‐lowering agents: Post hoc analyses from <scp>DECLARE‐TIMI</scp> 58

    Cardiorenal outcomes with dapagliflozin by baseline glucose‐lowering agents: Post hoc analyses from <scp>DECLARE‐TIMI</scp> 58 di Avivit Cahn, Stephen D. Wiviott, Ofri Mosenzon, Sabina A. Murphy, Erica L. Goodrich, Ilan Yanuv, Aliza Rozenberg, John Wilding, Lawrence A. Leiter, Deepak L. Bhatt, Darren K. McGuire, León Litwak, Adriaan Kooy, Ingrid Gause‐Nilsson, Martin Fredriksson, Anna Maria Langkilde, Marc S. Sabatine, Itamar Raz

    Pubblicazione 2020
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  13. 13
    Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study

    Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study di Avivit Cahn, Ofri Mosenzon, Stephen D. Wiviott, Aliza Rozenberg, Ilan Yanuv, Erica L. Goodrich, Sabina A. Murphy, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John Wilding, Ingrid Gause‐Nilsson, Martin Fredriksson, Peter A. Johansson, Anna Maria Langkilde, Marc S. Sabatine, Itamar Raz

    Pubblicazione 2019
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  14. 14
    Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58

    Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58 di Marc P. Bonaca, Stephen D. Wiviott, Thomas A. Zelniker, Ofri Mosenzon, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, Erica L. Goodrich, Remo Furtado, John Wilding, Avivit Cahn, Ingrid Gause‐Nilsson, Per Johanson, Martin Fredriksson, Peter A. Johansson, Anna Maria Langkilde, Itamar Raz, Marc S. Sabatine

    Pubblicazione 2020
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  15. 15
    Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in <scp>DECLARE‐TIMI</scp> 58

    Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in... di Thomas A. Zelniker, David A. Morrow, Ofri Mosenzon, Erica L. Goodrich, Petr Jarolı́m, Sabina A. Murphy, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John Wilding, Christoph Bode, Basil S. Lewis, Ingrid Gause‐Nilsson, Anna Maria Langkilde, Martin Fredriksson, Itamar Raz, Marc S. Sabatine, Stephen D. Wiviott

    Pubblicazione 2020
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  16. 16
    Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes

    Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes di Thomas A. Zelniker, Itamar Raz, Ofri Mosenzon, Jamie P. Dwyer, Hiddo H. J. L. Heerspink, Avivit Cahn, Erica L. Goodrich, KyungAh Im, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John Wilding, Ingrid Gause‐Nilsson, Anna Maria Langkilde, Marc S. Sabatine, Stephen D. Wiviott

    Pubblicazione 2021
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  17. 17
    Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus

    Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus di Thomas A. Zelniker, Marc P. Bonaca, Remo H.M. Furtado, Ofri Mosenzon, Julia Kuder, Sabina A. Murphy, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John Wilding, Andrzej Budaj, Róbert Gábor Kiss, Francisco Padilla, Ingrid Gause‐Nilsson, Anna Maria Langkilde, Itamar Raz, Marc S. Sabatine, Stephen D. Wiviott

    Pubblicazione 2020
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  18. 18
    Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial

    Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial di Meir Schechter, Stephen D. Wiviott, Itamar Raz, Erica L. Goodrich, Aliza Rozenberg, Ilan Yanuv, Sabina A. Murphy, Thomas A. Zelniker, Martin Fredriksson, Peter A. Johansson, Lawrence A. Leiter, Deepak L. Bhatt, Darren K. McGuire, John Wilding, Ingrid Gause‐Nilsson, Avivit Cahn, Anna Maria Langkilde, Marc S. Sabatine, Ofri Mosenzon

    Pubblicazione 2023
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  19. 19
    Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction

    Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction di Remo H.M. Furtado, Marc P. Bonaca, Itamar Raz, Thomas A. Zelniker, Ofri Mosenzon, Avivit Cahn, Julia Kuder, Sabina A. Murphy, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John Wilding, Christian T. Ruff, José Carlos Nicolau, Ingrid Gause‐Nilsson, Martin Fredriksson, Anna Maria Langkilde, Marc S. Sabatine, Stephen D. Wiviott

    Pubblicazione 2019
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  20. 20
    Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

    Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes di Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca, Ofri Mosenzon, Eri Kato, Avivit Cahn, Michael G. Silverman, Thomas A. Zelniker, Julia Kuder, Sabina A. Murphy, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John Wilding, Christian T. Ruff, Ingrid Gause‐Nilsson, Martin Fredriksson, Peter A. Johansson, Anna-Maria Langkilde, Marc S. Sabatine

    Pubblicazione 2018
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:

Strumenti per la ricerca: